US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
How Diddy made himself the 'victim' in apology video where he does not mention ex
Sean 'Diddy' Combs made himself sound like a victim in the Instagram apology video he posted in the2024-05-21Confucius Institute in Nepal lauded during 1st inaugural anniversary
(Xinhua) 09:39, August 17, 2023The Confucius Institute at Tribhuvan University celebrates its first2024-05-21- (Xinhua) 14:24, September 21, 2023HANOI, Sept. 21 (Xinhua) -- An evening for Chinese traditional art2024-05-21
Chinese scientists precisely monitor solar radiation on Earth's surface
(Xinhua) 13:17, December 02, 2023BEIJING, Dec. 1 (Xinhua) -- A Chinese team has developed a high-pre2024-05-21Jude Bellingham's new model girlfriend Laura Celia Valk looks sensational in a figure
Jude Bellingham's new girlfriend Laura Celia Valk looked sensational in a figure-hugging white dress2024-05-21Baidu strongly denies rumor of link between its AI tool and China’s military research
(Global Times) 08:02, January 16, 2024China's tech giant Baidu on Monday strongly denied allegations2024-05-21
atest comment